Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis
Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis
复制标题
血清 microRNA-29a 是一种有前途的早期检测结直肠肝转移的新型标记物
DOI：
10.1016/j.canep.2011.05.002
复制
发表时间：
2012-02-01
影响因子：
2.6
通讯作者：
Gu, Jin
中科院分区：
文献类型：
--
作者：
Wang, Long-gang;Gu, Jin
背景：结直肠癌（Colorectal cancer，CRC）转移发生于多种器官，以肝脏转移最多.血清学检查包括肿瘤和生化标志物用于肝功能评估，但其准确性不高。microRNA（miRNAs）与包括癌症在内的多种人类疾病有关，并且具有理想生物标志物的许多特征，最显著的是其固有的稳定性和弹性。最近，一些研究表明，循环miRNA作为癌症和其他疾病过程的新型非侵入性生物标志物具有很大的潜力。本研究的目的是探讨血清miRNA作为结直肠癌肝转移新生物标志物的潜力。研究方法：本研究分三个阶段进行：（1）采用实时荧光定量RT-PCR方法检测3种候选miRNAs，分别对应38例有肝转移的结直肠癌患者和36例无肝转移的结直肠癌患者。(II)通过实时RT-PCR对年龄和性别匹配的无肝转移（n = 20）和有肝转移（n = 20）的CRC患者的相似队列进行标记验证。(III)我们研究了候选血清miRNAs的表达与CRC患者临床参数之间的相关性。结果：结直肠癌肝转移（CRLM）患者血清miR-29 a水平显著高于结直肠癌患者。该标记物产生的受试者工作特征曲线面积为80.3%。在0.155的临界值，敏感性为75%，特异性为75%，在区分转移性和非转移性患者。此外，与CRC患者相比，在CRLM患者的结直肠肿瘤中也观察到miR-29 a表达水平增加。转移性和非转移性患者的血清miR-92 a水平无显著差异。结论：这些发现表明，血清miR-29 a具有作为早期检测CRC肝转移的新型非侵入性生物标志物的强大潜力。皇冠版权所有（C）2011由爱思唯尔有限公司出版。保留所有权利。
Background: Colorectal cancer (CRC) metastasis occurs in various organs, most frequently in liver. Serological examination including tumor and biochemical markers for liver function evaluation is routinely performed, though its accuracy is not high. MicroRNAs (miRNAs) have been implicated in a variety of human diseases including cancer, and have many characteristics of an ideal biomarker most notably their inherent stability and resilience. Recently, several studies have indicated that circulating miRNAs hold much potential as novel noninvasive biomarkers for cancer and other disease processes. The objective of this study was to investigate the potential of serum miRNAs as novel biomarkers for CRC with liver metastasis. Methods: This study was divided into three phases: (I) 3 candidate serum miRNAs were detected by using real-time RT-PCR, corresponding 38 CRC patients with liver metastasis and 36 CRC patients without metastasis. (II) Marker validation by real-time RT-PCR on a similar cohort of age- and sex-matched CRC patients without (n = 20) and with liver metastasis (n = 20). (III) We examined the correlation between the expressions of candidate serum miRNAs with clinical parameters of CRC patients. Results: Serum miR-29a was significantly higher in colorectal liver metastasis (CRLM) patients than in CRC patients. This marker yielded a receiver operating characteristic curve area of 80.3%. At a cutoff value of 0.155, the sensitivity was 75% and the specificity was 75% in discriminating metastatic from non-metastatic patients. In addition, increased levels of miR-29a expression were also observed in colorectal tumors from CRLM patients compared with CRC patients. No significant difference was observed in the levels of serum miR-92a between metastatic and non-metastatic patients. Conclusions: These findings suggest that serum miR-29a has strong potential as a novel noninvasive biomarker for early detection of CRC with liver metastasis. Crown Copyright (C) 2011 Published by Elsevier Ltd. All rights reserved.